Compare Novo Nordisk A/S (NVO) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Sibanye Stillwater Ltd — how do they compare? Novo Nordisk A/S trades at $44.72 (market cap $200.69B), while Sibanye Stillwater Ltd trades at $13.14 (market cap $9.35B). The key difference: Novo Nordisk A/S is far larger — about 21.5× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (6.27%). Which is the better fit depends on your goals.
| NVO | SBSW | |
|---|---|---|
Market Cap | $200.69B | $9.35B |
Sector | Health | Basic Materials |
52-Week High | $63.98 | $21.12 |
52-Week Low | $35.29 | $8.00 |
Enterprise Value | $215.49B | $10.29B |
Dividend Yield | 3.98% | 6.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
SBSW trades at $12.90, up 0.86% today, with a bullish technical signal from moving averages and ADX indicators. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26, and the company reported a strong turnaround in operating cash flow to $21.41 billion in 2025. Valuation ratios appear attractive with a P/E of 10.2 and EV/EBITDA of 5.2, while analyst consensus is a Buy with a $14.00 price target.
The outlook is positive due to robust earnings performance and improving cash flows, but risks include volatile commodity prices and high debt levels. Investment opportunity lies in potential upside to the consensus target, supported by operational momentum and disciplined capital allocation plans highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
